A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01028222
First received: December 7, 2009
Last updated: November 30, 2015
Last verified: November 2015

December 7, 2009
November 30, 2015
June 2010
December 2014   (final data collection date for primary outcome measure)
Overall Response Rate (ORR) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
ORR was defined as the proportion of participants with a best overall response (BOR) of a confirmed complete response or partial response (CR+PR) determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
To compare the clinical efficacy of nilotinib to DTIC based on progression free survival (PFS). [ Time Frame: Every 3 weeks until week 12, then every 6 weeks until week 24, then every 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01028222 on ClinicalTrials.gov Archive Site
  • Durable Overall Response Rate (DORR) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    DORR was defined as the rate of best overall response (CR+PR) lasting at least 12 weeks determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). The duration of ORR responders is computed from the date of first documented response (CR/PR) to the date of first documented progression or death due to underlying disease. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
  • Progression Free Survival (PFS) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a >=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
  • Overall Survival (OS) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
  • Time to Objective Response (TOR) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    TOR was defined as the time between the start date of treatment until first documented confirmed response of CR or PR determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
  • Disease Control Rate (DCR) [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    DCR was defined as the proportion of participants with an overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from start of treatment. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions; PD, a >=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; SD: no change or small changes that do not meet previously given criteria for CR, PR or PD.
  • PFS Rate [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a >=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
  • OS Rate [ Time Frame: End of study (up to 39 months) ] [ Designated as safety issue: No ]
    OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
  • To compare objective overall response rate (ORR) between nilotinib and DTIC. [ Time Frame: Every 3 weeks until week 12, then every 6 weeks until week 24, then every 12 weeks ] [ Designated as safety issue: No ]
  • To compare durable objective response rate (DORR) between nilotinib and DTIC [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • To compare overall survival (OS) between nilotinib and DTIC [ Time Frame: Every 3 weeks until week 12, then every 6 weeks until week 24, then every 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.

This trial began as a multi-center, randomized, Phase III, controlled trial for nilotinib vs (DTIC) dacarbazine to assess the efficacy and safety of nilotinib (400 mg bid) in patients with c-Kit mutated metastatic and/or inoperable melanoma. The study was open to patients with mucosal or acral melanoma.

Due to substantial difficulties identifying and recruiting eligible patients, the trial design was altered from a randomized, two-arm, Phase III study to a single-arm, Simon two-stage Phase II study with protocol Amendment 2 (27-Jul-2011). While the original protocol required the recruitment of 120 patients, this amendment required the study to recruit only 41 patients (patients randomized to nilotinib prior to Amendment 2 were to be counted in this total, but those randomized to dacarbazine ( DTIC ) DTIC were not). Patients randomized to DTIC were allowed to cross-over to nilotinib, either immediately or at the time of progression.

Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Melanoma
  • Drug: Nilotinib
    Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
    Other Name: AMN107
  • Drug: DTIC
    DTIC was supplied locally as sterile powder for i.v. infusion.
    Other Name: Dacarbazine
  • Experimental: Nilotinib
    400 mg twice daily
    Intervention: Drug: Nilotinib
  • Active Comparator: DTIC
    850 mg/m2 IV every 3 weeks
    Intervention: Drug: DTIC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

1. Histologically confirmed mucosal or acral 2. Presence of a c-Kit mutation of exon 9, 11 or 13, or mutations Y822D and mutations D820Y, Y823D of exon 17, as confirmed by the central laboratory 3. Stage III unresectable or stage IV disease 4. The presence of one or more measurable lesions as detected by radiological or photographic methods and assessed according to RECIST 1.0. Lesions must have a size of at least 10mm at longest diameter (using a slice thickness of 5 mm)or double the slice thickness to be considered a target lesion. Target lesions should not be selected in previously irradiated fields unless there is clear evidence of progression 5. WHO performance status 0 - 2

Exclusion Criteria:

  1. C-Kit mutation of exons 17(except mutations D820Y, Y822D or Y823D) or any other exon not allowed by the inclusion criteria
  2. Patients with c-Kit amplifications only and no mutation
  3. Patients with any history of brain metastases
  4. Patients who have had any prior treatment with TKIs
  5. Patients receiving medications or herbal extracts which interfere with nilotinib metabolism which are not discontinued by the time of the baseline visit
  6. Acute or chronic liver or renal disease considered unrelated to melanoma

Other protocol-defined inclusion/exclusion criteria may have applied.

Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Australia,   Belgium,   Brazil,   Canada,   China,   Germany,   Italy,   Netherlands,   Singapore,   Spain,   Sweden,   Switzerland
Poland,   Thailand
 
NCT01028222
CAMN107B2301, 2009-015514-21
Not Provided
Not Provided
Not Provided
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP